Group 1 - The core point of the article is that Derui Zhiyao has initiated Phase III clinical trials for its AI-designed oral weight loss drug MDR-001, marking it as the first AI-designed drug to reach this stage in China, offering new hope in the global weight loss treatment field [1][2] - MDR-001 was developed in just 4.5 years, significantly faster than the traditional 7 to 9 years required for similar innovative drugs, thanks to AI-assisted design [1][2] - The AI platform, Molecule Pro™, enables large-scale "intelligent screening" and "risk warning," allowing for the rapid creation of millions of new molecular structures and early safety assessments of candidate molecules [1][2] Group 2 - The Phase IIb trial results for MDR-001 showed a weight reduction of 10.3% in patients after 24 weeks, indicating its strong therapeutic potential and safety advantages [2] - Derui Zhiyao plans to recruit approximately 750 overweight or obese participants for a 52-week systematic evaluation, with the drug expected to be launched by the end of 2028 or in 2029 if all goes well [2] - The Hangzhou Medical Port, where Derui Zhiyao is located, has over 1,800 biopharmaceutical companies and has achieved an industry revenue exceeding 50 billion yuan, with 132 innovative drugs entering clinical trials, the highest in the city [3]
中国首款AI设计减重药冲刺上市
Hang Zhou Ri Bao·2026-01-12 02:43